Drug Profile

Research programme: CNS disorders and substance-related disorders therapeutics - Kinoxis Therapeutics

Latest Information Update: 28 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Sydney
Developer Kinoxis Therapeutics
Class Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules
Mechanism of Action Oxytocin receptor antagonists; Oxytocin receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2023 No recent reports of development identified for preclinical development in CNS-disorders in Australia (PO)
12 Apr 2023 Early research in Post-traumatic stress disorders in Australia (PO) (Kinoxis Therapeutics pipeline, April 2023)
12 Apr 2023 Preclinical trials in Mental disorders in Australia (PO) (Kinoxis Therapeutics pipeline, April 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com